Chronic myeloid leukaemia
19-04-2017 | Chronic myeloid leukaemia | News | Article
First-line generic imatinib offers ‘suboptimal efficacy’
For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.
Clin Lymphoma Myeloma Leuk 2017; Advance online publication
12-04-2017 | Chronic myeloid leukaemia | News | Article
Molecular response depth may predict imatinib resistance risk
Study findings suggest that the depth of molecular response to imatinib achieved by a patient with chronic myeloid leukemia may influence the relationship between a fluctuating response to treatment and the likelihood of developing resistance to the tyrosine kinase inhibitor.
Br J Haematol 2017; Advance online publication
3D breast cancer/© Sebastian Kaulitzki - Fotolia, Breast cancer_silhouette/© goa novi / fotolia.com, Intestines_sketch/© T. L. Furrer - Fotolia, Plasma samples_DNA/© blindturtle / stock.adobe.com, brain scan cancer 2, Male thyroid anatomy/© CLIPAREA.com / Fotolia, lung_cancer, melanoma_skin cancer, Woman_microscope/© WavebreakMediaMicro / Fotolia, brain scan cancer 2